{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:40:47Z","timestamp":1784943647176,"version":"3.55.0"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T00:00:00Z","timestamp":1537228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0409-8","type":"journal-article","created":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T12:36:11Z","timestamp":1537274171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer"],"prefix":"10.1136","volume":"6","author":[{"given":"Jason M.","family":"Redman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,9,18]]},"reference":[{"issue":"8","key":"409_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"4","key":"409_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375\u201384.","journal-title":"Lancet Oncol."},{"issue":"19","key":"409_CR3","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"10031","key":"409_CR4","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet"},{"issue":"10064","key":"409_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67\u201376.","journal-title":"Lancet"},{"issue":"4","key":"409_CR6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00277-017-2931-z","volume":"96","author":"TS Chan","year":"2017","unstructured":"Chan TS, Luk TH, Lau JS, Khong PL, Kwong YL. Low-dose pembrolizumab for relapsed\/refractory Hodgkin lymphoma: high efficacy with minimal toxicity. Ann Hematol. 2017;96(4):647\u201351.","journal-title":"Ann Hematol"},{"key":"409_CR7","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of Pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction Cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;15 [Epub ahead of print]."},{"issue":"34","key":"409_CR8","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, Nivolumab, in patients with platinum-resistant ovarian Cancer. J Clin Oncol. 2015;33(34):4015\u201322.","journal-title":"J Clin Oncol"},{"issue":"12","key":"409_CR9","doi-asserted-by":"publisher","first-page":"e0189848","DOI":"10.1371\/journal.pone.0189848","volume":"12","author":"BH O'Neil","year":"2017","unstructured":"O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One. 2017;12(12):e0189848.","journal-title":"PLoS One"},{"issue":"4","key":"409_CR10","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812\u201330 e14.","journal-title":"Immunity"},{"issue":"7","key":"409_CR11","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700\u201312.","journal-title":"Lancet Oncol."},{"issue":"1","key":"409_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","volume":"35","author":"TM Beer","year":"2017","unstructured":"Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of Ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate Cancer. J Clin Oncol. 2017;35(1):40\u20137.","journal-title":"J Clin Oncol"},{"issue":"26","key":"409_CR13","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"suppl 6","key":"409_CR14","first-page":"abstr 725PD","volume":"27","author":"A Hansen","year":"2016","unstructured":"Hansen A, Massard C, Ott P, Haas N, Lopez J, Ejadi S, et al. Pembrolizumab for patients with advanced prostate adenocarcinoma: preliminary results from the KEYNOTE-028 study. Ann Oncol. 2016;27(suppl 6):abstr 725PD.","journal-title":"Ann Oncol"},{"issue":"5","key":"409_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411\u201322.","journal-title":"N Engl J Med"},{"issue":"6","key":"409_CR16","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.ajpath.2018.02.014","volume":"188","author":"MC Haffner","year":"2018","unstructured":"Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, et al. Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate Cancer. Am J Pathol. 2018;188(6):1478\u201385.","journal-title":"Am J Pathol"},{"issue":"11","key":"409_CR17","doi-asserted-by":"publisher","first-page":"dju268","DOI":"10.1093\/jnci\/dju268","volume":"106","author":"L Fong","year":"2014","unstructured":"Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014;106(11):dju268.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"409_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1172\/JCI38379","volume":"120","author":"RI Fernando","year":"2010","unstructured":"Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest. 2010;120(2):533\u201344.","journal-title":"J Clin Invest"},{"issue":"18","key":"409_CR19","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.1158\/1078-0432.CCR-14-0421","volume":"20","author":"F Pinto","year":"2014","unstructured":"Pinto F, Pertega-Gomes N, Pereira MS, Vizcaino JR, Monteiro P, Henrique RM, et al. T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness. Clin Cancer Res. 2014;20(18):4949\u201361.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"409_CR20","doi-asserted-by":"publisher","first-page":"6833","DOI":"10.1158\/1078-0432.CCR-17-1087","volume":"23","author":"CR Heery","year":"2017","unstructured":"Heery CR, Palena C, McMahon S, Donahue RN, Lepone LM, Grenga I, et al. Phase I study of a Poxviral TRICOM-based vaccine directed against the transcription factor Brachyury. Clin Cancer Res. 2017;23(22):6833\u201345.","journal-title":"Clin Cancer Res"},{"issue":"424","key":"409_CR21","doi-asserted-by":"publisher","first-page":"eaan5488","DOI":"10.1126\/scitranslmed.aan5488","volume":"10","author":"Y Lan","year":"2018","unstructured":"Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-beta. Sci Transl Med. 2018;10(424):eaan5488.","journal-title":"Sci Transl Med"},{"issue":"10","key":"409_CR22","doi-asserted-by":"publisher","first-page":"e1349589","DOI":"10.1080\/2162402X.2017.1349589","volume":"6","author":"JM David","year":"2017","unstructured":"David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, Palena C. A novel bifunctional anti-PD-L1\/TGF-beta trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology. 2017;6(10):e1349589.","journal-title":"Oncoimmunology"},{"issue":"7693","key":"409_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138.","journal-title":"Nature"},{"issue":"6","key":"409_CR24","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","volume":"24","author":"J Strauss","year":"2018","unstructured":"Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFbeta, in advanced solid tumors. Clin Cancer Res. 2018;24(6):1287\u201395.","journal-title":"Clin Cancer Res"},{"issue":"4 suppl","key":"409_CR25","doi-asserted-by":"crossref","first-page":"abstr 100","DOI":"10.1200\/JCO.2018.36.4_suppl.100","volume":"36","author":"Y Kang","year":"2018","unstructured":"Kang Y, Doi T, Kondo S, Chung H, Muro K, Helwig C, et al. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in Asian patients with pretreated recurrent or refractory gastric cancer: Preliminary results from a phase I trial. J Clin Oncol. 2018;36(4 suppl):abstr 100.","journal-title":"J Clin Oncol"},{"issue":"1","key":"409_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","volume":"4","author":"PR Rhode","year":"2016","unstructured":"Rhode PR, Egan JO, Xu W, Hong H, Webb GM, Chen X, et al. Comparison of the Superagonist complex, ALT-803, to IL15 as Cancer Immunotherapeutics in animal models. Cancer Immunol Res. 2016;4(1):49\u201360.","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"409_CR27","doi-asserted-by":"publisher","first-page":"16130","DOI":"10.18632\/oncotarget.7470","volume":"7","author":"PS Kim","year":"2016","unstructured":"Kim PS, Kwilas AR, Xu W, Alter S, Jeng EK, Wong HC, et al. IL-15 superagonist\/IL-15RalphaSushi-fc fusion complex (IL-15SA\/IL-15RalphaSu-fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget. 2016;7(13):16130\u201345.","journal-title":"Oncotarget"},{"key":"409_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cyto.2017.12.003","volume":"107","author":"B Liu","year":"2018","unstructured":"Liu B, Jones M, Kong L, Noel T, Jeng EK, Shi S, et al. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. Cytokine. 2018;107:105\u201312.","journal-title":"Cytokine"},{"issue":"4","key":"409_CR29","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00262-018-2121-4","volume":"67","author":"R Fujii","year":"2018","unstructured":"Fujii R, Jochems C, Tritsch SR, Wong HC, Schlom J, Hodge JW. An IL-15 superagonist\/IL-15Ralpha fusion complex protects and rescues NK cell-cytotoxic function from TGF-beta1-mediated immunosuppression. Cancer Immunol Immunother. 2018;67(4):675\u201389.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"409_CR30","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","volume":"19","author":"JM Wrangle","year":"2018","unstructured":"Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19(5):694\u2013704.","journal-title":"Lancet Oncol"},{"issue":"17","key":"409_CR31","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","volume":"115","author":"X Liu","year":"2010","unstructured":"Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010;115(17):3520\u201330.","journal-title":"Blood"},{"issue":"13","key":"409_CR32","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1182\/blood-2006-03-006700","volume":"108","author":"M Della Chiesa","year":"2006","unstructured":"Della Chiesa M, Carlomagno S, Frumento G, Balsamo M, Cantoni C, Conte R, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood. 2006;108(13):4118\u201325.","journal-title":"Blood"},{"issue":"9","key":"409_CR33","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1084\/jem.189.9.1363","volume":"189","author":"DH Munn","year":"1999","unstructured":"Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189(9):1363\u201372.","journal-title":"J Exp Med"},{"issue":"4","key":"409_CR34","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.4049\/jimmunol.0900986","volume":"183","author":"B Baban","year":"2009","unstructured":"Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol. 2009;183(4):2475\u201383.","journal-title":"J Immunol"},{"key":"409_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2051-1426-2-3","volume":"2","author":"S Spranger","year":"2014","unstructured":"Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer. 2014;2:3.","journal-title":"J Immunother Cancer"},{"issue":"25","key":"409_CR36","doi-asserted-by":"publisher","first-page":"37762","DOI":"10.18632\/oncotarget.9326","volume":"7","author":"C Jochems","year":"2016","unstructured":"Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, et al. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. Oncotarget. 2016;7(25):37762\u201372.","journal-title":"Oncotarget"},{"issue":"15 suppl","key":"409_CR37","doi-asserted-by":"publisher","first-page":"abstr 3003","DOI":"10.1200\/JCO.2017.35.15_suppl.3003","volume":"35","author":"R Perez","year":"2017","unstructured":"Perez R, Riese M, Lewis K, Saleh M, Daud A, Berlin J, et al. Epacadostat plus nivolumab in patients with advanced solid tumors: preliminary phase I\/II results of ECHO-204. J Clin Oncol. 2017;35(15 suppl):abstr 3003.","journal-title":"J Clin Oncol"},{"issue":"31","key":"409_CR38","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.1200\/JCO.2013.50.3201","volume":"31","author":"S Halabi","year":"2013","unstructured":"Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, et al. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2013;31(31):3944\u201350.","journal-title":"J Clin Oncol"},{"issue":"7","key":"409_CR39","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","volume":"28","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099\u2013105.","journal-title":"J Clin Oncol"},{"issue":"1","key":"409_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1\u201310.","journal-title":"Control Clin Trials"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0409-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0409-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0409-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:43:56Z","timestamp":1601055836000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0409-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,18]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["409"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0409-8","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,18]]},"assertion":[{"value":"31 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial was approved by the Institutional Review Board of the Center for Cancer Research, National Cancer Institute ( identifier: NCT03493945).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No patient data were discussed in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"91"}}